Three Directors Resign from Tempest Therapeutics Board Amidst Going Concern Warning
summarizeSummary
Three directors, Stephen Brady, Michael Raab, and Christine Pellizzari, resigned from Tempest Therapeutics' Board of Directors, effective May 22, 2026.
check_boxKey Events
-
Multiple Director Resignations
Mr. Stephen Brady, Mr. Michael Raab, and Ms. Christine Pellizzari resigned from the Board of Directors, effective May 22, 2026.
-
No Disagreement Stated
The company reported that the resignations were not due to any disagreement regarding operations, policies, or practices.
-
Waiver of Retainer Fees
The departing directors waived all accrued and unpaid retainer fees as part of their Separation Agreements.
-
Indemnification and Stock Rights Maintained
Their outstanding stock option awards, ownership of shares, and indemnification rights remain unaffected by the resignations.
auto_awesomeAnalysis
The simultaneous resignation of three directors from the Board of Directors is a significant governance event, particularly for a micro-cap company like Tempest Therapeutics that recently issued a 'going concern' warning. While the company stated the resignations were not due to disagreements, such a substantial change in board composition can raise questions about strategic direction, stability, and investor confidence during a critical period for the company's financial viability and ongoing clinical programs.
At the time of this filing, TPST was trading at $1.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.5M. The 52-week trading range was $1.50 to $12.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.